Eli Lilly Immunology — Revenue increased by 13.1% to $1.54B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.4%, from $1.29B to $1.54B. Over 4 years (FY 2021 to FY 2025), Immunology — Revenue shows an upward trend with a 11.8% CAGR.
lly_segment_immunology_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $785.40M | $1.00B | $956.60M | $748.10M | $796.50M | $866.40M | $933.60M | $777.80M | $928.50M | $986.90M | $1.10B | $834.00M | $1.08B | $1.19B | $1.29B | $1.09B | $1.26B | $1.36B | $1.54B |
| QoQ Change | — | +27.9% | -4.8% | -21.8% | +6.5% | +8.8% | +7.8% | -16.7% | +19.4% | +6.3% | +11.9% | -24.5% | +29.8% | +9.5% | +8.9% | -15.7% | +15.4% | +8.5% | +13.1% |
| YoY Change | — | — | — | — | +1.4% | -13.8% | -2.4% | +4.0% | +16.6% | +13.9% | +18.3% | +7.2% | +16.6% | +20.1% | +16.9% | +30.5% | +16.0% | +14.9% | +19.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.